Zdrowie i gospodarka · 31/12/2024
FDA Reopens Comment Period for Host Cell Proteins in Recombinant Peptide Products
The FDA is reopening the comment period for its request for information and comments notice regarding the evaluation of immunogenicity risk in follow-on recombinant peptide products, allowing for updates and new information.